About this trial
The goal of this observational study is to continuously assess cerebral autoregulation in patients with subarachnoid hemorrhage (SAH) using cerebral oximetry index (COx) and hemoglobin volume reactivity index (HVx). The main question it aims to answer is: Whether optimal perfusion pressure is dynamic and changes with time in patients with SAH, and that autoregulation is disrupted in patients during the course of SAH, contributing to delayed cerebral ischemia (DCI).
Eligibility criteria
Qualifiers
Patients aged 18 to 89 years who are admitted to the Neurological Intensive Care Unit (Neuro ICU) between March 2025 and December 2026 for aneurysmal subarachnoid hemorrhage (SAH).
Disqualifiers
Patients under 18 years old
Prisoners
Pregnant women
Patients enrolled in concurrent ongoing interventional trial
Trial design
Treatments tested in this trial
- - Non-Invasive Near-infrared Spectroscopy (NIRS) device (HEM1 with Foresight Elite Sensor)
Treatment groups
Sponsors and collaborators
University of Alabama at Birmingham
Lead sponsor
Edwards Lifesciences
Collaborator